Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
- DOI
- 10.1136/jitc-2021-003844
- Published
- 2022 Feb
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2021-003844,
title = {Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.},
author = {Tykodi SS and Gordan LN and Alter RS and Arrowsmith E and Harrison MR and Percent I and Singal R and Van Veldhuizen P and George DJ and Hutson T and Zhang J and Zoco J and Johansen JL and Rezazadeh Kalebasty A},
year = {2022},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2021-003844},
url = {https://doi.org/10.1136/jitc-2021-003844}
}RIS
TY - JOUR TI - Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. AU - Tykodi SS AU - Gordan LN AU - Alter RS AU - Arrowsmith E AU - Harrison MR AU - Percent I AU - Singal R AU - Van Veldhuizen P AU - George DJ AU - Hutson T AU - Zhang J AU - Zoco J AU - Johansen JL AU - Rezazadeh Kalebasty A PY - 2022 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2021-003844 UR - https://doi.org/10.1136/jitc-2021-003844 ER -
APA
SS, T., LN, G., RS, A., E, A., MR, H., I, P., R, S., P, V. V., DJ, G., T, H., J, Z., J, Z., JL, J., & A, R. K. (2022). Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2021-003844
Source records
- pubmed · retrieved 2026-09-26T03:25:26.981Z